Literature DB >> 15342414

Fas signaling is involved in the control of hair follicle response to chemotherapy.

Andrei A Sharov1, Frank Siebenhaar, Tatyana Y Sharova, Natalia V Botchkareva, Barbara A Gilchrest, Vladimir A Botchkarev.   

Abstract

Chemotherapeutic agents induce p53-dependent apoptosis in the hair follicle (HF) resulting in hair loss, a common side effect of cancer therapy. Here, we show that Fas as a p53 target plays important role in the HF response to cyclophosphamide. Specifically, we demonstrate that Fas is up-regulated in HF keratinocytes after cyclophosphamide treatment, Fas ligand-neutralizing antibody partially inhibits HF response to cyclophosphamide in wild-type mice, and Fas knockout mice show significant retardation of cyclophosphamide-induced HF involution associated with reduced Fas-associated death domain and caspase-8 expression. These data raise a possibility to explore blockade of Fas signaling as a part of complex local therapy for inhibiting keratinocyte apoptosis and hair loss induced by chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15342414     DOI: 10.1158/0008-5472.CAN-04-1367

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  p53/p63/p73 in the epidermis in health and disease.

Authors:  Vladimir A Botchkarev; Elsa R Flores
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-01       Impact factor: 6.915

2.  Laminin-511, inducer of hair growth, is down-regulated and its suppressor in hair growth, laminin-332 up-regulated in chemotherapy-induced alopecia.

Authors:  Hisayoshi Imanishi; Daisuke Tsuruta; Chiharu Tateishi; Koji Sugawara; Ralf Paus; Tsutomu Tsuji; Masamitsu Ishii; Kazuo Ikeda; Hiroyuki Kunimoto; Koichi Nakajima; Jonathan C R Jones; Hiromi Kobayashi
Journal:  J Dermatol Sci       Date:  2010-02-16       Impact factor: 4.563

3.  Involvement of the Edar signaling in the control of hair follicle involution (catagen).

Authors:  Michael Y Fessing; Tatyana Y Sharova; Andrey A Sharov; Ruzanna Atoyan; Vladimir A Botchkarev
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

4.  Testing chemotherapeutic agents in the feather follicle identifies a selective blockade of cell proliferation and a key role for sonic hedgehog signaling in chemotherapy-induced tissue damage.

Authors:  Guojiang Xie; Hangwei Wang; Zhipeng Yan; Linyan Cai; Guixuan Zhou; Wanzhong He; Ralf Paus; Zhicao Yue
Journal:  J Invest Dermatol       Date:  2014-09-18       Impact factor: 8.551

5.  Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy.

Authors:  Eniko Bodó; Desmond J Tobin; York Kamenisch; Tamás Bíró; Mark Berneburg; Wolfgang Funk; Ralf Paus
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

6.  Complex changes in the apoptotic and cell differentiation programs during initiation of the hair follicle response to chemotherapy.

Authors:  Tatyana Y Sharova; Krzysztof Poterlowicz; Natalia V Botchkareva; Nikita A Kondratiev; Ahmar Aziz; Jeffrey H Spiegel; Vladimir A Botchkarev; Andrey A Sharov
Journal:  J Invest Dermatol       Date:  2014-07-07       Impact factor: 8.551

7.  SOCS3 treatment prevents the development of alopecia areata by inhibiting CD8+ T cell-mediated autoimmune destruction.

Authors:  Zhen Gao; Yu-Qing Jin; Wei Wu
Journal:  Oncotarget       Date:  2017-05-16

8.  CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane-induced alopecia.

Authors:  Talveen S Purba; Kayumba Ng'andu; Lars Brunken; Eleanor Smart; Ellen Mitchell; Nashat Hassan; Aaron O'Brien; Charlotte Mellor; Jennifer Jackson; Asim Shahmalak; Ralf Paus
Journal:  EMBO Mol Med       Date:  2019-09-12       Impact factor: 12.137

9.  Role for the epidermal growth factor receptor in chemotherapy-induced alopecia.

Authors:  Kyle J Bichsel; Navdeep Gogia; Timothy Malouff; Zachary Pena; Eric Forney; Brianna Hammiller; Patrice Watson; Laura A Hansen
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.